ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO413

Development of Novel Cell Therapeutic Strategies for AKI and CKD Using Human Induced Pluripotent Stem Cell (iPSC)-Derived Nephron Progenitor Cells

Session Information

Category: Development, Stem Cells, and Regenerative Medicine

  • 600 Development, Stem Cells, and Regenerative Medicine

Authors

  • Araoka, Toshikazu, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Kyoto, Japan
  • Toyohara, Kosuke, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Kyoto, Japan
  • Ryosaka, Makoto, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Kyoto, Japan
  • Matsuura, Maasa, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Kyoto, Japan
  • Osafune, Kenji, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Kyoto, Japan
Background

The therapeutic effect of human iPS cell-derived nephron progenitor cells (hiPSC-NPCs) on acute kidney injury (AKI) has been reported in mice but has not been clinically confirmed. No reported studies have examined the therapeutic potential of hiPSC-NPCs on chronic kidney disease (CKD). On the other hand, it was recently reported that the properties of hiPSC-NPCs differ depending on differences in iPSC lines and batches among experiments. Therefore, a large number of uniform hiPSC-NPCs are required to realize cell therapies for AKI and CKD, but effective expansion cultures remain to be developed.

Methods

We screened culture conditions that maintained the function of hiPSC-NPCs by multiple combinations of the low-molecular-weight compounds and growth factors. Furthermore, we transplanted expanded hiPSC-NPCs into the renal subcapsule of cisplatin-induced AKI model (cis-AKI) mice and aristolochic acid-induced CKD model (AA-CKD) mice and evaluated renal function and histological changes. We also administered conditioned medium (CM) produced by expanded hiPSC-NPCs to cis-AKI mice to examine the therapeutic effects, and performed mass spectrometry of CM and RNA-sequencing of hiPSC-NPCs.

Results

We established a novel expansion culture condition (CFY medium) that enables more than 1,000-fold proliferation of hiPSC-NPCs in three passages while maintaining NPC marker expression. We demonstrated that hiPSC-NPCs expanded by CFY medium attenuate kidney injury and improve survival rate in cis-AKI mice. Furthermore, we found that hiPSC-NPCs prevent kidney functional decline, interstitial fibrosis, and senescence in AA-CKD mice. In addition, the contralateral kidneys transplanted with hiPSC-NPCs in AKI and CKD mice were also treated, suggesting that the therapeutic effects of hiPSC-NPCs were due to reno-protective factors. Therefore, we administered CM produced by expanded hiPSC-NPCs to cis-AKI mice, which prevented kidney functional decline and improved survival rate. Furthermore, we identified some reno-protective factors contained in CM and demonstrated that angiogenesis in the injured kidney is involved as part of the mechanisms by which hiPSC-NPCs exert therapeutic effects.

Conclusion

The expanded hiPSC-NPCs are useful for cell therapies for AKI and CKD and will open new avenues in the treatment of kidney diseases.

Funding

  • Commercial Support – Rege Nephro Co., Ltd